No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice

Blood Cells, Molecules, and Diseases

Volumn 57, Issue , 2016, Pages 67-70

  Choi, Erika ^a   Branch, Craig ^b   Cui, Min Hui ^b   Yazdanbakhsh, Karina ^a   Mohandas, Narla ^a   Billett, Henny H ^b   Shi, Patricia A ^a,b  

^a NEW YORK BLOOD CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Endothelial cell activation; Hematopoietic progenitor cell mobilization; Neutrophil activation; Platelet activation; Plerixafor; Sickle cell disease

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PADGEM PROTEIN; PLERIXAFOR; CHEMOKINE RECEPTOR CXCR4; CXCL12 PROTEIN, MOUSE; HETEROCYCLIC COMPOUND; PROTEIN BINDING; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL OCCLUSION; BRAIN BLOOD VESSEL; CELL ACTIVATION; CELL POPULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEMATOPOIETIC STEM CELL; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SICKLE CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; ANEMIA, SICKLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW; CEREBROVASCULAR DISORDERS; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROCEDURES; STEM CELL MOBILIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE;

ANEMIA, SICKLE CELL; ANIMALS; BONE MARROW; CEREBROVASCULAR DISORDERS; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, TRANSGENIC; PROTEIN BINDING; RECEPTORS, CXCR4;

EID: 84959186003     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2015.12.008     Document Type: Article

References (16)

1. Fitzhugh C.D., Hsieh M.M., Bolan C.D., Saenz C., Tisdale J.F. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?. Cytotherapy 2009, 11:464-471.
2. Yannaki E., Papayannopoulou T., Jonlin E., Zervou F., Karponi G., Xagorari A., Becker P., Psatha N., Batsis I., Kaloyannidis P., Tahynopoulou V., Constantinou V., Bouinta A., Kotta K., Athanassiadou A., Anagnostopoulos A., Fassas A., Stamatoyannopoulos G. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol. Ther. 2012, 20:230-238.
3. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., Liles W.C., Li X., Graham-Evans B., Campbell T.B., Calandra G., Bridger G., Dale D.C., Srour E.F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. Isr. J. Exp. Med. 2005, 201:1307-1318.
4. Molineux G., Kinstler O., Briddell B., Hartley C., McElroy P., Kerzic P., Sutherland W., Stoney G., Kern B., Fletcher F.A., Cohen A., Korach E., Ulich T., McNiece I., Lockbaum P., Miller-Messana M.A., Gardner S., Hunt T., Schwab G. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp. Hematol. 1999, 27:1724-1734.
5. K.F., Paxinos G. Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates 2012, Academic Press.
6. Kennan R.P., Suzuka S.M., Nagel R.L., Fabry M.E. Decreased cerebral perfusion correlates with increased BOLD hyperoxia response in transgenic mouse models of sickle cell disease. Magn. Reson. Med. 2004, 51:525-532.
7. Christensen J.L., Weissman I.L. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14541-14546.
8. Saraceni F., Shem-Tov N., Olivieri A., Nagler A. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant. 2015, 50:886-891.
9. Yannaki E., Karponi G., Zervou F., Constantinou V., Bouinta A., Tachynopoulou V., Kotta K., Jonlin E., Papayannopoulou T., Anagnostopoulos A., Stamatoyannopoulos G. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with beta-thalassemia major. Hum. Gene Ther. 2013, 24:852-860.
10. Zarbock A., Ley K. Neutrophil adhesion and activation under flow. Microcirculation 2009, 16:31-42.
11. Kappelmayer J., Nagy B., Miszti-Blasius K., Hevessy Z., Setiadi H. The emerging value of P-selectin as a disease marker. Clin. Chem. Lab. Med. CCLM/FESCC 2004, 42:475-486.
12. Spiel A.O., Bartko J., Schwameis M., Firbas C., Siller-Matula J., Schuetz M., Weigl M., Jilma B. Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial. Thromb. Haemost. 2011, 105:655-662.
13. Rao K.M., Currie M.S., Cohen H.J., Peters W.P. Alterations in L-selectin expression and elastase activity in neutrophils from patients receiving granulocyte colony-stimulating factor alone or in conjunction with high-dose chemotherapy with autologous bone marrow transplantation. Lymphokine Cytokine Res. 1994, 13:383-390.
14. Oelschlaegel U., Bornhauser M., Boxberger S., Kroschinsky F., Illmer T., Hoelig K., Calandra G., Ehninger G., Platzbecker U. Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma. Ann. Hematol. 2007, 86:569-573.
15. Manci E.A., Hillery C.A., Bodian C.A., Zhang Z.G., Lutty G.A., Coller B.S. Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood 2006, 107:1651-1658.
16. Venketasubramanian N., Prohovnik I., Hurlet A., Mohr J.P., Piomelli S. Middle cerebral artery velocity changes during transfusion in sickle cell anemia. Stroke 1994, 25:2153-2158.